Anti-synthetic antibodies are a dubious disease in the field of autoimmune and rheumatic immunity, clinical manifestations are complex and often involve multi-system fatigue. Early identification and standardized diagnosis are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical manifestations, imaging inspections, laboratory tests and pathological activation.
The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of anti-synthetic synthetic antibodies requires individualized development of treatment programs, typically including drug therapy, rehabilitation interventions, and regular follow-up programs. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immune disorders that were previously difficult to treat have been significantly improved.
Therapeutic efficacy and adverse reactions need to be closely monitored and timely adjusted according to changes in the course of treatment. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of anti-synthesis syndrome accompanied by anti-nuclear antibodies. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.